Shares of Arkema SA (OTCMKTS:ARKAY – Get Free Report) have received a consensus recommendation of “Reduce” from the seven analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have given a hold recommendation to the company.
A number of analysts recently weighed in on the company. Barclays upgraded Arkema from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Arkema in a research note on Tuesday, June 23rd.
View Our Latest Stock Analysis on ARKAY
Arkema Stock Up 0.7%
Arkema (OTCMKTS:ARKAY – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The basic materials company reported $1.98 earnings per share for the quarter, beating analysts’ consensus estimates of $1.86 by $0.12. Arkema had a return on equity of 4.30% and a net margin of 0.67%. The business had revenue of $2.79 billion for the quarter, compared to the consensus estimate of $2.86 billion. As a group, research analysts expect that Arkema will post 3.73 earnings per share for the current fiscal year.
About Arkema
Arkema is a France-based specialty materials company that develops and manufactures materials used in a broad range of industrial and consumer applications. Its portfolio includes high-performance polymers, adhesives, coating materials, additives and specialty chemical intermediates.
The company’s businesses serve markets such as construction, automotive, electronics, renewable energy, consumer goods, packaging and healthcare. Arkema’s brands and product lines include Bostik adhesives, Kynar fluoropolymers, Rilsan polyamide materials, Pebax elastomers and Sartomer specialty resins and additives.
Arkema was established in 2004 through the reorganization of Total’s chemicals businesses and became an independent, publicly traded company in 2006.
See Also
- Five stocks we like better than Arkema
- 3 Unique ETFs With Strong Momentum for the End of the Year
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
- Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone?
- Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining
Receive News & Ratings for Arkema Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arkema and related companies with MarketBeat.com's FREE daily email newsletter.
